Natural lipid acts as potent anti-inflammatory10 Jul 2018
Scientists see therapeutic potential against bacteria, viruses.
National Institutes of Health (NIH) researchers have identified a naturally occurring lipid used by a disease-causing bacterium to impair the host immune response and increase the chance of infection. Inadvertently, they also may have found a potent inflammation therapy against bacterial and viral diseases.
Lipids are known to help Francisella tularensis bacteria, the cause of tularemia, to suppress host inflammation when infecting mouse and human cells. In a new study published in the Journal of Innate Immunity, researchers from NIH’s National Institute of Allergy and Infectious Diseases found a form of the lipid phosphatidylethanoloamine, or PE, present in the bacterium. The composition of PE found in F. tularensis differs from PE found in other bacteria. In cell-culture experiments, the researchers discovered that the natural and a synthetic form of PE reduced inflammation caused by both tularemia bacteria and dengue fever virus.
Tularemia is a life-threatening disease spread to humans via contact with an infected animal or through the bite of a mosquito, tick or deer fly. Although tularemia can be successfully treated with antibiotics, it is difficult to diagnose, mainly because F. tularensis bacteria can suppress the human immune response. Dengue fever, primarily spread by Aedes aegypti mosquitoes, is rarely fatal but usually leads to a high fever, severe headache and pain throughout the body. There is no specific treatment for dengue fever.
After identifying PE as the lipid that impaired the immune response, the scientists began to consider its potential therapeutic value. Because natural F. tularensis is highly infectious and therefore challenging to work with, the group developed synthetic lipids — PE2410 and PEPC2410 — that would be much easier to study and produce. They then verified that both synthetic lipids also suppressed the immune response during infection of mouse and human cells in the laboratory.
Because several types of viral infections involve an unconstrained inflammatory response, the group tested natural and their synthetic PE in the laboratory against dengue fever virus-infected human cells. Both versions inhibited the immune response compared to the immune response seen in infected but untreated cells.
The group plans to continue exploring how F. tularensis impairs the immune response. They hope their findings will eventually lead to the development of a potent, broad-spectrum anti-inflammatory therapeutic.
Plasticell leads gene therapy manufacturing consortium
3 Jul 2018
Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.Read more
Follicum develops new direct-to-scalp formulation
27 Jun 2018
The topical treatment for hair loss boasts a 'commercial' formulation.Read more
Collaboration to provide GMP-based services
19 Jun 2018
Researchers to benefit by receiving a rapid and cost-effective scaled supply of new compounds.Read more
Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs
5 Jun 2018
TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.Read more
Anti-vedolizumab antibodies to support treatment research
25 May 2018
A reliable source of antibodies for the development of bioanalytical assays for vedolizumab, to support research into the treatment of ulcerative colitis and Crohn’s diseaseRead more
The shortest way from the lab to continuous production
24 May 2018
Bosch's new Xelum R&D for continuous production of oral solid dosage forms ensures a short time-to-market and optimum dosing of APIs.Read more
Comparative analysis of a complex monoclonal antibody
24 May 2018
New poster describes how the EAF4 module enabled simultaneous measurement of size and surface charge characteristics of antibodies and proteins.Read more
Lilly expands oncology pipeline with acquisition
16 May 2018
Acquisition of AurKa Pharma expands Lilly's oncology pipeline with early-phase asset being studied in multiple tumour types.Read more
Versatile lyophilizer for research, development or small-scale production
15 May 2018
Allows for easy and intuitive scale-up from research.Read more
New online customer portal for custom research services
14 May 2018
Customers to gain a greater insight into their projects, better track project progress and improve communications.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation